Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics
Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics
复制标题
DOI：
10.1097/yic.0b013e328338bc5a
复制
发表时间：
2010-07-01
影响因子：
2.6
通讯作者：
Matute, Carlos
中科院分区：
文献类型：
--
作者：
Gonzalez-Pinto, Ana;Mosquera, Fernando;Matute, Carlos
一些临床前和尸检研究表明，非典型抗精神病药物的作用可能是由脑源性神经营养因子（BDNF）介导的。奥氮平是一种非典型抗精神病药物，在精神病治疗中显示出疗效。本研究的目的是比较18例首次精神病发作的药物初治患者和18例年龄、性别和社会经济水平匹配的健康对照参与者在基线和奥氮平治疗1年后的血浆BDNF水平。采用酶联免疫吸附试验测定患者在指数发作时和随访1、6和12个月时的血浆BDNF水平。采用阳性和阴性症状量表和功能总体评定量表对患者和对照组的症状和功能进行评定。在奥氮平治疗期间，患者的BDNF水平在发病时显著低于对照组，但向对照值增加。脑源性神经营养因子水平与功能（总体功能评估量表）呈显著正相关。BDNF水平也与阳性症状呈负相关，但与阴性症状或一般精神病理学无关。结果表明，奥氮平可以抵消第一次精神病发作时的低BDNF水平，并改善精神病症状。BDNF水平的增加可能是其改善阳性症状的作用机制。Int Clin Psychopharmacol 25：241-245（C）2010 Wolters Kluwer Health vertical bar Lippincott威廉姆斯& Wilkins.
Some preclinical and postmortem studies suggest that the effects of atypical antipsychotics could be mediated by brain-derived neurotrophic factor (BDNF). Olanzapine is an atypical antipsychotic with shown efficacy in psychosis treatment. The aim of this study was to compare plasma BDNF levels at baseline and after 1 year of olanzapine treatment in 18 drug-naive patients who experienced a first psychotic episode with those of 18 healthy control participants matched by age, sex, and socioeconomic level. Plasma BDNF levels were measured in patients at the index episode and at 1, 6, and 12 months of follow-up using an enzyme-linked immunosorbent assay. Symptoms and functioning of patients and controls were assessed with the Positive and Negative Symptom Scale and Global Assessment of Function Scale. BDNF levels of patients at onset were significantly lower than controls but increased toward control values during olanzapine treatment. There was a significant positive correlation between BDNF levels and functioning ( Global Assessment of Function Scale). BDNF levels were also negatively correlated with positive symptoms, but not with negative symptoms or general psychopathology. Results suggest that olanzapine can offset the low BDNF levels at the onset of first psychotic episodes, and improving psychotic symptoms. The increase in BDNF levels may be its mechanism of action in improving positive symptoms. Int Clin Psychopharmacol 25: 241-245 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.